These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4073928)

  • 1. [The antitumor activity of intraperitoneally- or orally-administered etoposide in animals and its administration-schedule dependency].
    Okamoto K; Nishikawa K; Seki T; Shibasaki C; Uchida T; Takahashi K
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2331-7. PubMed ID: 4073928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
    Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antitumor activity by long-term administration of low-dose etoposide].
    Kusama K; Ekimoto H; Ishii T; Okamoto K; Takahashi K
    Gan To Kagaku Ryoho; 1991 May; 18(6):959-63. PubMed ID: 2029199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I clinical study of NK 171 (etoposide)].
    Kimura K; Yamada K; Niitani H
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):851-6. PubMed ID: 2985006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
    Furusawa S; Mian AM
    Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental studies on oral administration of nitrosourea anti-tumor agent, MCNU].
    Sekido S; Ninomiya K; Araki T; Ueno M; Kinbara M
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1492-500. PubMed ID: 6234861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumor activities of orally administered 4-carbamoylimidazolium-5-olate (SM-108)].
    Nakamura M; Fukui M; Morisada S; Inaba M; Tsukagoshi S; Sakurai Y
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2030-6. PubMed ID: 4051519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
    Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.